Compare Citius Pharmaceuticals Inc (CTXR) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Wolfspeed Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Wolfspeed Inc trades at $34.7 (market cap $1.78B). The key difference: Wolfspeed Inc is far larger — about 121.6× Citius Pharmaceuticals Inc's market cap, and Wolfspeed Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | WOLF | |
|---|---|---|
Market Cap | $14.64M | $1.78B |
Sector | Health | Technology |
52-Week High | $1.82 | $73.68 |
52-Week Low | $0.53 | $1.19 |
Enterprise Value | $10.86M | $2.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Wolfspeed (WOLF) trades at $33.65, down 4.65% today amid bearish technical signals and negative profitability metrics. The stock shows mixed earnings performance with recent beats but a significant Q4 2025 miss. Recent developments include a patent lawsuit against Navitas Semiconductor and strategic partnerships with GE Aerospace, positioning the company in high-growth AI and defense markets despite current financial challenges.
The outlook remains cautious with analyst consensus leaning neutral (47.37% Hold). While strategic pivots to data centers and defense offer growth potential, negative margins and bearish technicals present near-term risks. Investors should monitor earnings improvement and market share gains in silicon carbide technology for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
